Eventide Asset Management LLC Has $35.24 Million Position in Zymeworks Inc.

Trending News ☀️

Zymeworks Intrinsic Value – Eventide Asset Management LLC has a $35.24 million position in Zymeworks($NYSE:ZYME) Inc Eventide Asset Management LLC is a Boston-based investment firm. The news of Eventide’s investment in Zymeworks Inc has caused some investors to question whether this will have a positive or negative effect on Zymeworks’ market and earnings in the long term. Some believe that Eventide’s investment is a vote of confidence in Zymeworks and will help to boost the company’s stock price. However, others are concerned that the large investment could put pressure on Zymeworks to perform well in the future and that any dips in performance could lead to a sell-off by Eventide.

Market Price

On Tuesday, ZYMEWORKS stock opened at $4.9 and closed at $5.0, up by 1.2% from prior closing price of 4.9.

VI Analysis – Zymeworks Intrinsic Value

Zymeworks Inc is a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, which are engineered to have greater efficacy and durability than existing monotherapy treatments. The company’s proprietary platform, ZymeLink, is designed to combine multiple functions into one therapy to address complex disease targets. ZymeLink is also designed to allow for the construction of novel fusion proteins and the development of next-generation antibody-drug conjugates . Zymeworks has a strong pipeline of candidate therapeutics in various stages of development, including four clinical-stage candidates and two preclinical-stage candidates. The company’s fundamentals reflect its long-term potential. The fair value of Zymeworks shares is around $24.2, calculated by VI Line. Now Zymeworks stock is traded at $5.0, undervalued by 79%.

Summary

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Finally, Van ECK Associates Corp lifted its stake in shares of Zymeworks by 5.0% during the third quarter. Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes proprietary multifunctional biotherapeutics in Canada.